Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

Gudra D, Shoaie S, Fridmanis D, Klovins J, Wefer H, Silamikelis I, Peculis R, Kalnina I, Elbere I, Radovica-Spalvina I, Hultcrantz R, Šķenders Ģ, Leja M, Engstrand L.

Gut. 2019 Sep;68(9):1723-1725. doi: 10.1136/gutjnl-2018-316225. Epub 2018 Sep 21. No abstract available.

2.

Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types.

Brancaccio RN, Robitaille A, Dutta S, Cuenin C, Santare D, Skenders G, Leja M, Fischer N, Giuliano AR, Rollison DE, Grundhoff A, Tommasino M, Gheit T.

Virology. 2018 Jul;520:1-10. doi: 10.1016/j.virol.2018.04.017. Epub 2018 May 7.

3.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

4.

Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey.

Pavlenko E, Barbova A, Hovhannesyan A, Tsenilova Z, Slavuckij A, Shcherbak-Verlan B, Zhurilo A, Vitek E, Skenders G, Sela I, Cabibbe AM, Cirillo DM, de Colombani P, Dara M, Dean A, Zignol M, Dadu A.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):197-205. doi: 10.5588/ijtld.17.0254.

PMID:
29506617
5.

Tuberculosis cases caused by heterogeneous infection in Eastern Europe and their influence on outcomes.

Kontsevaya I, Nikolayevskyy V, Kovalyov A, Ignatyeva O, Sadykhova A, Simak T, Tikhonova O, Dubrovskaya Y, Vasiliauskiene E, Davidaviciene E, Skenders G, Makurina O, Balabanova Y, Drobniewski F.

Infect Genet Evol. 2017 Mar;48:76-82. doi: 10.1016/j.meegid.2016.12.016. Epub 2016 Dec 18.

6.

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages.

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Henry Boom W, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S.

Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31.

7.

MIRU-VNTR genotype diversity and indications of homoplasy in M. avium strains isolated from humans and slaughter pigs in Latvia.

Kalvisa A, Tsirogiannis C, Silamikelis I, Skenders G, Broka L, Zirnitis A, Jansone I, Ranka R.

Infect Genet Evol. 2016 Sep;43:15-21. doi: 10.1016/j.meegid.2016.05.013. Epub 2016 May 11.

PMID:
27178993
8.

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.

Stagg HR, White PJ, Riekstiņa V, Cīrule A, Šķenders Ģ, Leimane V, Kuksa L, Dravniece G, Brown J, Jackson C.

Emerg Infect Dis. 2016 Mar;22(3):482-90. doi: 10.3201/eid2203.151227.

9.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

10.

Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes.

Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van den Bergh R, Kremer K, Acosta CD, Harries AD.

Public Health Action. 2014 Oct 21;4(Suppl 2):S47-53. doi: 10.5588/pha.14.0041.

11.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

12.

Genotypic and phenotypic characteristics of aminoglycoside-resistant Mycobacterium tuberculosis isolates in Latvia.

Bauskenieks M, Pole I, Skenders G, Jansone I, Broka L, Nodieva A, Ozere I, Kalvisa A, Ranka R, Baumanis V.

Diagn Microbiol Infect Dis. 2015 Mar;81(3):177-82. doi: 10.1016/j.diagmicrobio.2014.12.004. Epub 2014 Dec 15.

PMID:
25557624
13.

Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease.

Nikolayevskyy V, Miotto P, Pimkina E, Balabanova Y, Kontsevaya I, Ignatyeva O, Ambrosi A, Skenders G, Ambrozaitis A, Kovalyov A, Sadykhova A, Simak T, Kritsky A, Mironova S, Tikhonova O, Dubrovskaya Y, Rodionova Y, Cirillo D, Drobniewski F.

Tuberculosis (Edinb). 2015 Mar;95(2):179-85. doi: 10.1016/j.tube.2014.11.005. Epub 2014 Dec 9.

PMID:
25534168
14.

Laboratory diagnosis of paediatric tuberculosis in the European Union/European Economic Area: analysis of routine laboratory data, 2007 to 2011.

Sanchini A, Fiebig L, Drobniewski F, Haas W, Richter E, Katalinic-Jankovic V, Pimkina E, Skenders G, Cirillo DM; European Reference Laboratory Network for TB Members, Balabanova Y.

Euro Surveill. 2014 Mar 20;19(11). pii: 20744.

15.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

16.

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators, Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P.

Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum in: Lancet. 2012 Oct 20;380(9851):1386.

PMID:
22938757
17.

Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study.

Mironova S, Pimkina E, Kontsevaya I, Nikolayevskyy V, Balabanova Y, Skenders G, Kummik T, Drobniewski F.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1381-7. doi: 10.1007/s10096-011-1453-1. Epub 2011 Oct 25.

PMID:
22037774
18.

Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.

Skenders GK, Holtz TH, Riekstina V, Leimane V.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1546-52, i. doi: 10.5588/ijtld.11.0067.

PMID:
22008771
19.

Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.

Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, Juréen P, Hoffner S, Del Portillo P, Morcillo N, Palomino JC.

J Antimicrob Chemother. 2011 Apr;66(4):827-33. doi: 10.1093/jac/dkq527. Epub 2011 Jan 19.

PMID:
21393176
20.

Rifampin-isoniazid oligonucleotide typing: an alternative format for rapid detection of multidrug-resistant Mycobacterium tuberculosis.

Hernández-Neuta I, Varela A, Martin A, von Groll A, Jureen P, López B, Imperiale B, Sķenders G, Ritacco V, Hoffner S, Morcillo N, Palomino JC, Del Portillo P.

J Clin Microbiol. 2010 Dec;48(12):4386-91. doi: 10.1128/JCM.00448-10. Epub 2010 Sep 29.

21.

Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis.

Nodieva A, Jansone I, Broka L, Pole I, Skenders G, Baumanis V.

Int J Tuberc Lung Dis. 2010 Apr;14(4):427-33.

PMID:
20202300
22.

Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004.

Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH.

Eur Respir J. 2010 Sep;36(3):584-93. doi: 10.1183/09031936.00003710. Epub 2010 Feb 25.

23.

Recommended standards for modern tuberculosis laboratory services in Europe.

Drobniewski FA, Hoffner S, Rusch-Gerdes S, Skenders G, Thomsen V; WHO European Laboratory Strengthening Task Force.

Eur Respir J. 2006 Nov;28(5):903-9. Epub 2006 Aug 9.

24.

Multidrug-resistant tuberculosis detection, Latvia.

Skenders G, Fry AM, Prokopovica I, Greckoseja S, Broka L, Metchock B, Holtz TH, Wells CD, Leimane V.

Emerg Infect Dis. 2005 Sep;11(9):1461-3.

25.

Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis.

Tracevska T, Jansone I, Nodieva A, Marga O, Skenders G, Baumanis V.

Res Microbiol. 2004 Dec;155(10):830-4.

PMID:
15567277
26.

Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia.

Tracevska T, Jansone I, Baumanis V, Nodieva A, Marga O, Skenders G.

Antimicrob Agents Chemother. 2004 Aug;48(8):3209-10. No abstract available.

27.

Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: first experience with a quality control panel in the Nordic-Baltic collaboration.

Johansen IS, Larsen AR, Sandven P, Petrini B, Soini H, Levina K, Sosnovskaja A, Skenders G, Hoffner S.

Int J Tuberc Lung Dis. 2003 Sep;7(9):899-902.

PMID:
12971676

Supplemental Content

Loading ...
Support Center